Tharimmune, Inc.

10/19/2023

We are pleased to share that CEO Randy Milby is presenting in-person at the ThinkEquity Conference in NYC today at 10AM ET | Lotus Suite West. Webcast available to registered attendees.

www.tharimmune.com

09/22/2023

Hillstream BioPharma (Nasdaq: HILS) is thrilled to announce a corporate name change to Tharimmune, Inc! The company’s common stock will trade on Nasdaq under a new ticker symbol, THAR (Nasdaq: THAR), effective as of Monday, September 25, 2023.

"Over the past few months, we have made significant progress in shifting the focus of the Company to align with our future vision to impact patients in serious need of new treatment options. Our new name, dedicated to the courage of all people diagnosed with diseases of high unmet need, aligns with this focus as we shift into a patient-centric organization striving towards developing impactful and accessible products,” said Randy Milby, Chairman and CEO of Tharimmune, Inc.

Tharimmune is also progressing towards acquiring a clinical stage asset, TH104, with a recently approved IND. We expect to close the acquisition in the fourth quarter as well launch and complete a phase 1 pharmacokinetic trial by year-end.

Read here for more details: https://bit.ly/3PPATAj

09/14/2023

In case you missed it: Hillstream BioPharma CEO Randy Milby joined Benzinga's All Access show last week to discuss current developments in the company’s pipeline, our lead program HSB-3215, and what’s on the horizon.

Watch the interview here: https://bit.ly/48a23ch

Check out www.benzinga.com for complete coverage along with all the latest financial news and data!Follow us Online!📸Instagram: www.instagram.com/benzinga👍...

09/11/2023

Hillstream BioPharma (Nasdaq: HILS) is thrilled to announce an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved Investigational New Drug (IND) application.

Hillstream intends to first seek approval of AV104 in an orphan disease for the treatment of moderate to severe cholestatic pruritis in patients with primary biliary cholangitis (PBC), a rare form of liver disease with no known cure.

Read the details of our latest development here: https://bit.ly/3sP2UyO

09/11/2023

Hillstream CEO Randy Milby will virtually present recent progress in targeting drug-resistant cancers at the H.C. Wainwright & Co., LLC 25th Annual Global Investment Conference today.

Details may be found here: https://bit.ly/45Yac1k

09/08/2023

Hillstream BioPharma (Nasdaq: HILS) to Present at H.C. Wainwright 25th Annual Global Investment Conference on September 11th at 7:00am ET.

Read the full news release here: https://bit.ly/45Yac1k

08/30/2023

In case you missed it: Hillstream BioPharma CEO Randy Milby recently appeared on Benzinga’s All Access show to provide updates on:

- Background and experience
- HSB-3215, Hillstream’s candidate for human antibodies targeting novel HER2 and HER3
- A recent collaboration with Minotaur Therapeutics and future partnership prospects
- Hillstream’s scientific advisory board

Tune in here:

Randy Milby, CEO of Hillstream BioPharma (NASDAQ: HILS), was a guest on Benzinga’s All-Access.

08/25/2023

TODAY: Hillstream CEO Randy Milby joins Benzinga’s All-Access to discuss the driving factors behind our mission to develop enhanced targeted cancer immunotherapy with lead HER2/HER3 program HSB-3215, our recent collaboration with Minotaur Therapeutics, and plan of action for the latter half of 2023 and into 2024.

Stream the interview to hear Randy’s insight here:

On LIVE Trading with Benzinga, we'll be providing you with trade ideas every weekday morning from 9am-11am ET.-----------------------------------------------...

08/16/2023

Hillstream BioPharma will present at the Sidoti Micro-Cap Virtual Conference today.

“Sidoti has fostered a strong tight-knit group of movers and shakers within the micro-cap world, and we believe this group will be a good fit for understanding our true value proposition as we continue to make advancements with our HER2/HER3 program and transform Hillstream into a focused and targeted cancer biologics company,” says CEO Randy Milby.

Our management team will also hold virtual 1-on-1 meetings with institutional investors and analysts who are interested in learning more. Register here to watch: https://sidoti.zoom.us/webinar/register/WN_VNIDaCOURnKEjyhrbSdtUQ #/registration

08/09/2023

Scientific Advisory Board Spotlight: Dr. Vaughn Smider provides Hillstream BioPharma with immense research expertise in molecular medicine and germline antibody repertoires.

Dr. Smider currently serves as an adjunct faculty member of Scripps Research Institute and previously led their Molecular Medicine Department’s research lab. He is also the founder of Ta**us Biosciences as well as the founder and CSO of Fabrus LLC and Sevion Therapeutics.

Learn more about our team of experts: https://hillstreambio.com/about/

08/09/2023

Hillstream BioPharma (Nasdaq: HILS) to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023.

Read the full news release here: https://www.globenewswire.com/news-release/2023/08/09/2721669/0/en/Hillstream-BioPharma-to-Present-at-the-Sidoti-Micro-Cap-Virtual-Conference-on-August-16-17-2023.html #:~:text=(Nasdaq%3A%20HILS)%20

08/02/2023

Scientific Advisory Board Spotlight: Dr. John Lambert, Ph.D

Dr. Lambert is a leading expert in the field of Antibody-Drug Conjugate (ADC) discovery and development and has held leadership positions at ImmunoGen, inventor of the ADC technology that resulted in Kadcyla and mirvetuximab soravtansine, for the treatment of HER2+ breast cancer and platinum-resistant ovarian cancer.

Dr. Lambert has also authored or co-authored over 120 peer-reviewed scientific publications.

Learn more about our team of experts: https://hillstreambio.com/about/